Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett*s Epithelium - Efficacy EBCA focal

C2Therapeutics0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•a) Patients with known Barrett*s esophagus, scheduled for treatment with focal radiofrequency ablation (HALO-90) [i.e. in patients with islands or residual Barrett*s after circumferential radiofrequency ablation (HALO-360) or in patients for whom circumferential radiofrequency ablation is not feasible], during which the cryoablation may be performed.
•b) Patient is 18 to 80 years of age at the time of consent (inclusive).
•c) Patient has provided written Informed Consent (IC) using an Informed Consent Form (ICF) that has been approved by the Institution*s reviewing IRB/EC.
•d) Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
•e) Patient is deemed operable per standard institutional criteria.
•f) Each patient will have one (group of) island of BE *1 cm2 where the Cryoballoon Focal Ablation System can be successfully positioned within the BE lesion.
•g) BE lesion within the treatment zone should be flat.

•a) Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4 cm of treatment zone.
•b) Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post treatment instructions or follow-up guidelines.
•c) Patient refuses or is unable to provide written informed consent.
•d) Patients that are pregnant.
•e) Patient with endoscopically active inflammation in the treatment zone.
•f) Endoscopically visible abnormalities such as masses or nodules requiring endoscopic resection.

发起方

C2Therapeutics